Perrigo Co. (PRGO) announced Monday morning that it agreed to acquire Rosemont Pharmaceuticals Ltd. for approximately $283 million in cash. Rosemont is expected to be $0.08 accretive to adjusted EPS for the remainder of fiscal 2013. Perrigo now expects fiscal 2013 adjusted earnings to be between $5.53 and $5.73 per diluted share as compared to $4.99 in fiscal 2012.
Perrigo gapped open higher Monday and is now up 1.63 at $109.93. The stock has risen to a 1-month high and has re-crossed its 200-day moving average.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.